InnoSIGN

InnoSIGN Commercializes Its Proprietary mRNA-Based OncoSIGNal Pathway Activity Profiling Technology, Revolutionizing Precision Medicine Through a Deeper Understanding of Disease Mechanisms. OncoSIGNal is Available as a Research-Use-Only qPCR Test for Decentralized Use and is Offered via Its Service Testing Facility Located in the Netherlands. InnoSIGN Leverages Its Extensive Database, Which Contains Over 100,000 Pathway Activity Profiles, to Support Diagnostics and Drug Development.